Piramal Critical Care Docks For China Push

 
• By Anju Ghangurde

Peter DeYoung, CEO of Piramal Critical Care, tells Scrip about his plans to take the group’s inhalation anesthesia portfolio to China and talks of the greater “competitive intensity” in the US amid quicker ANDA approvals by the FDA. Timelines around the potential US launch of the inhaled anesthetic agent, desflurane, however, appear hazy.

Peter De'Young
PIRAMAL CRITICAL CARE CEO PETER DEYOUNG

More from Business

More from Scrip